TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).
TapImmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately $6.82 million in a private placement transaction with accredited investors and from the exercise of certain outstanding Series E warrants by certain existing institutional investors.
Dr. Glynn Wilson, Chairman and CEO of TapImmune, will present at the 2017 Biotechnology Innovation Organization International Convention held on June 19-22 in San Diego.
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
Ovarian Cancer News Today has covered TapImmune’s cancer vaccine for Ovarian and Breast Cancer, TPIV 200. Take a look.
The company is getting closer with several therapies under development, CEO Glynn Wilson said in a quarterly update last week.
Here is the complete transcript provided by Seeking Alpha from May 31st conference call and live webcast regarding 2017 first quarter clinical and corporate updates.